Axogen, Inc. (AXGN)
AXGNAxogen is a developer of surgical solutions, including human tissue grafts, based in Alachua, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering (IPO). Axogen uses a cell graft technology AVANCE to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.
Drugs in Pipeline
1
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Processed Nerve Allograft (human) | Phase 3 | Peripheral Nerve Discontinuities | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Axogen, Inc. (AXGN)'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Axogen, Inc. (AXGN)'s (AXGN) pipeline across Phase 3. Its lead program is Processed Nerve Allograft (human) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Axogen, Inc. (AXGN)'s next FDA catalyst?→
Axogen, Inc. (AXGN)'s (AXGN) next tracked catalyst is a Earnings expected July 29, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track AXGN biotech catalysts?→
Add AXGN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Axogen, Inc. (AXGN)'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.